Brief Article
Copyright ©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 28, 2010; 16(44): 5621-5628
Published online Nov 28, 2010. doi: 10.3748/wjg.v16.i44.5621
Figure 1
Figure 1 Overall survival rates of patients with advanced gastric cancer in 12 studies (A), 3-year progression-free rates in 3 studies (B), tomor down-staging rates in 6 studies (C), R0 resection rates in 8 studies (D), and adverse effects of neoadjuvant chemotherapy (E). NAC: Neoadjuvant chemotherapy; PFS: Progression-free survival; CI: Confidence interval.